Globus Medical (NYSE:GMED) Sets New 52-Week High – Time to Buy?

Globus Medical, Inc. (NYSE:GMED)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $101.40 and last traded at $95.4510, with a volume of 1125592 shares. The stock had previously closed at $90.54.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Company raised FY2026 guidance (EPS $4.30–4.40 vs. consensus ~4.05) and revenue guidance ~ $3.2B, which underpins the rally. Globus Medical jumps 9% after upbeat revenue and earnings outlook
• Positive Sentiment: Management expects ~16.5% revenue growth for 2025, reinforcing the company’s durable top-line momentum and supporting higher forward estimates. Globus Medical expects 16.5% gains in 2025 revenue
• Positive Sentiment: Canaccord Genuity reiterated a Buy stance, which provides further buy-side validation after the updated guidance. Canaccord Genuity Remains a Buy on Globus Medical (GMED)
• Positive Sentiment: Zacks highlights GMED as a long-term growth idea based on style scores and growth metrics, supporting longer-term investor interest. Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: TipRanks / Needham maintained a Hold rating, noting strong fundamentals but suggesting much of the outperformance may already be priced in — a caution for near-term upside. Globus Medical: Strong Fundamentals and Outperformance Largely Priced In, Justifying a Hold Rating
• Negative Sentiment: A Seeking Alpha analysis warns that M&A assumptions and valuation dynamics could limit upside — investors should watch acquisition math and how it affects multiples going forward. Globus Medical 2026 Outlook: Why M&A Math Mires The Valuation

Analysts Set New Price Targets

GMED has been the subject of a number of recent analyst reports. Citigroup restated a “market perform” rating on shares of Globus Medical in a report on Thursday. Morgan Stanley boosted their price target on Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research report on Thursday. Bank of America raised Globus Medical from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $65.00 to $91.00 in a research report on Friday, November 7th. Finally, BTIG Research restated a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. Eight research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $97.78.

Globus Medical Trading Down 0.2%

The firm has a market capitalization of $12.64 billion, a P/E ratio of 30.46, a P/E/G ratio of 1.58 and a beta of 1.06. The stock has a 50 day simple moving average of $85.80 and a 200-day simple moving average of $67.89.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, November 6th. The medical device company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.39. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The company had revenue of $769.05 million for the quarter, compared to the consensus estimate of $734.58 million. During the same quarter last year, the firm posted $0.83 earnings per share. The firm’s revenue was up 22.9% compared to the same quarter last year. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. As a group, sell-side analysts expect that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ann D. Rhoads sold 8,000 shares of Globus Medical stock in a transaction on Friday, November 7th. The stock was sold at an average price of $81.00, for a total transaction of $648,000.00. Following the transaction, the director directly owned 17,384 shares in the company, valued at approximately $1,408,104. The trade was a 31.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen T. Zarrilli sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $84.29, for a total value of $2,107,250.00. The SEC filing for this sale provides additional information. Insiders sold 86,042 shares of company stock worth $7,419,030 in the last quarter. Company insiders own 18.51% of the company’s stock.

Institutional Trading of Globus Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Burgundy Asset Management Ltd. grew its holdings in Globus Medical by 24.3% during the 2nd quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock valued at $205,474,000 after buying an additional 679,691 shares in the last quarter. William Blair Investment Management LLC boosted its position in shares of Globus Medical by 17.2% during the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after acquiring an additional 414,134 shares during the last quarter. Sculptor Capital LP grew its stake in Globus Medical by 31.9% during the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after acquiring an additional 667,850 shares in the last quarter. Geneva Capital Management LLC increased its holdings in Globus Medical by 13.6% in the 2nd quarter. Geneva Capital Management LLC now owns 2,082,788 shares of the medical device company’s stock valued at $122,926,000 after acquiring an additional 249,141 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after purchasing an additional 1,908,795 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.